Pfizer Inc. and BioNTech SE on Wednesday said their COVID-19 vaccine was safe and effective and produced a robust antibody response in 12 to 15-year-olds, following a trial of 2,260 adolescents. Reggie Cecchini reports on what this means going forward for the Pfizer vaccine and what’s next in the effort to combat the pandemic.
- Pfizer’s COVID-19 shot less effective against South African variant: study
- Saskatchewan adds 2 new deaths, 191 new COVID-19 infections